|Articles|June 20, 2018

No Polio in Venezuela, But Challenges Remain: Public Health Watch

A reported case of the deadly disease was a misdiagnosis, but it is still a warning sign of the troubles facing the South American country.

These days, public health specialists and clinicians working on the ground in Venezuela follow one simple rule: Assume the worst.

At least that seems to be the case after reports surfaced last week that a 3-year-old child from the Warao indigenous community in the rural northeastern part of the country presented to a clinic with symptoms of paralysis consistent with polio. Officials notified the Pan-American Health Organization (PAHO), and headlines trumpeted that the troubled South American country was facing yet another public health crisis.

In 2018 alone, Venezuela has already confronted outbreaks of HIV, as reported by Contagion®, and measles. The latter has resulted in 70 deaths and now threatens communities in neighboring Colombia and Brazil.

“There are significant gaps in community protection through vaccination in [Venezuela],” Edwin J. Asturias, MD, Jules Amer Chair, Community Pediatrics, Children’s Hospital Colorado and associate professor, Pediatrics and Epidemiology, University of Colorado School of Medicine told Contagion®. Dr. Asturias has written extensively about health challenges in general, and vaccination specifically, in South America.

“These communities are also at risk of measles, diphtheria, and other infections that have already reemerged in the country and could be well prevented by a strong vaccination program,” he continued. “In Venezuela, the low vaccine coverage is being driven by the erosion of the health system due to the economic and political crisis. Every time a country dips into economic or political struggle, we see these diseases reemerging.”

It turns out, though, that at least with regard to polio, health officials had sounded a false alarm—this time. Within 1 day of the news that the country had its first documented case of the deadly disease since 1961, PAHO and the World Health Organization (WHO) issued a clarification: The child’s acute flaccid paralysis was not caused by polio; and, the child had, in fact, been vaccinated against the disease. As of this writing, the cause of the child’s symptoms remains unknown.

To be clear, this is not a criticism of health officials and providers in Venezuela. The country has been on the brink of collapse since the death of former president Hugo Chavez in 2013, though some would argue it was in trouble when the leader was still alive and in charge. As a result, the health infrastructure is in dire straits, hampered by medication shortages and crumbling facilities. Given the recent history of disease outbreaks and other crises, even in the most cosmopolitan regions of the country, a diagnosis of polio in a child from a poor, rural area where vaccine coverage is likely limited is hardly far-fetched.

Indeed, it’s important here to not accuse those working on the frontlines in Venezuela of “crying wolf.” Rather, the polio misdiagnosis should be considered a dodged bullet—for now.

“The main reason for these infections coming back is the lack of population immunity, meaning not enough people are protected with these life-saving vaccines,” Dr. Asturias said. “Polio easily transmits in communities when vaccine coverage is below 50%. The main challenge ahead is for organizations like the PAHO and other partners to be allowed to coordinate with the Venezuelan government to launch a massive campaign to rapidly provide immunity to children and those at risk in these areas of vulnerability.”

And if that doesn’t happen soon, clinicians working in the region are expecting the worst. In other words, sadly, it may only be a matter of time before a deadly diagnosis in Venezuela isn’t a misdiagnosis but a harbinger of things to come.

Brian P. Dunleavy is a medical writer and editor based in New York. His work has appeared in numerous health care-related publications. He is the former editor of Infectious Disease Special Edition.


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
FAQ: Ebola Prevention, Treatment and the Chances of a US Outbreak
As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.